Kalaris Therapeutics, Inc. (KLRS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 3, 2026, details the results of the 2026 Annual Meeting of Stockholders held by Kalaris Therapeutics, Inc. The filing covers corporate governance matters including director elections, executive compensation advisory votes, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on stockholder voting outcomes and does not contain financial performance data.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: Stockholders elected Napoleone Ferrara, M.D., David Hallal, and Leone Patterson as Class III directors for three-year terms. All three candidates received significant majority support with "For" votes exceeding 15.6 million each.
- Executive Compensation (Say-on-Pay): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers. The vote resulted in 15,852,844 "For" votes versus 495,763 "Against" votes.
- Frequency of Say-on-Pay: Stockholders recommended holding future advisory votes on executive compensation annually. The "One Year" option received 16,336,117 votes, overwhelmingly defeating the two-year and three-year options.
- Auditor Ratification: Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal passed with 19,771,260 "For" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The Board of Directors confirmed its intent to hold future advisory compensation votes annually based on the stockholder recommendation.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented at the meeting to assess the significance of the "Broker Non-Votes" (3,420,470).
- Confirm the specific terms of the three-year director terms for the newly elected Class III directors.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.
- Monitor the implementation of the annual Say-on-Pay frequency as recommended by stockholders.